Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity
Authors:
Open Access
- 23 March 2024
- journal article
- research article
- Published by Elsevier in Cell Reports
- Vol. 43 (4) , 114003
Abstract
No abstract availableKeywords
Funding Information
- China Pharmaceutical University (CPUQNJC22)
- National Key Research and Development Program of China (2022YFC2303200)
- National Natural Science Foundation of China (91949124, 32071259, 82271602, 81972894, 82022025)
- Shenzhen Science and Technology Innovation Committee (JCYJ20200109105001821, JCYJ20190808173601655)
- Ministry of Science and Technology of the People's Republic of China
This publication has 66 references indexed in Scilit:
- Hippo/YAP signaling choreographs the tumor immune microenvironment to promote triple negative breast cancer progression via TAZ/IL-34 axisCancer Letters, 2022
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- Unlocking the therapeutic potential of primary tumor-draining lymph nodesCancer Immunology, Immunotherapy, 2019
- LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint BlockadeCell, 2018
- Allele-Specific HLA Loss and Immune Escape in Lung Cancer EvolutionCell, 2017
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- The Hippo Pathway Kinases LATS1/2 Suppress Cancer ImmunityCell, 2016
- Transcriptional Co-repressor Function of the Hippo Pathway Transducers YAP and TAZCell Reports, 2015
- Switch Enhancers Interpret TGF-β and Hippo Signaling to Control Cell Fate in Human Embryonic Stem CellsCell Reports, 2013
- T cell receptor antagonist peptides induce positive selectionCell, 1994